Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    Epetraborole Granted Orphan Drug Designation for NTM Lung Disease
    pixabay.com

    Epetraborole Granted Orphan Drug Designation for NTM Lung Disease

    In a news release from February 16, 2022, clinical-stage biopharmaceutical company AN2 Therapeutics, Inc. ("AN2") shared that its therapy epetraborole was granted Orphan Drug designation for the treatment of non-tuberculous…

    Continue Reading Epetraborole Granted Orphan Drug Designation for NTM Lung Disease
    INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 2)
    Daniel de Boer. Photo courtesy of: ProQR and FTI Consulting

    INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 2)

    If you would like to read the first part of this interview, please take a look at Part 1 here. In the first part of the interview, I spoke with…

    Continue Reading INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 2)
    ICYMI: Swimmer’s 100km Swim Raised Huntington’s Disease Awareness
    Free-Photos / Pixabay

    ICYMI: Swimmer’s 100km Swim Raised Huntington’s Disease Awareness

    HTT gene mutations cause Huntington’s disease, a rare and inherited neurological condition. Those with a family history of Huntington’s disease may choose to undergo genetic testing to learn more, though…

    Continue Reading ICYMI: Swimmer’s 100km Swim Raised Huntington’s Disease Awareness
    INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 1)
    Daniel de Boer. Photo courtesy of: ProQR and FTI Consulting

    INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 1)

    Clinical trials, drug development, and medical research have the potential to change the therapeutic landscape for patients with a wide variety of conditions. At ProQR, founder and CEO Daniel de…

    Continue Reading INTERVIEW: How ProQR’s Sirius and Celeste Studies Could Change the Therapeutic Landscape for USH2A-Mediated RP and Usher Syndrome (Pt. 1)
    Georgia Retina Performs First Susvimo Implantation in State for Wet Macular Degeneration
    source: pixabay.com

    Georgia Retina Performs First Susvimo Implantation in State for Wet Macular Degeneration

    In October 2021, the FDA approved Susvimo (ranibizumab injection) for the treatment of wet age-related macular degeneration. Now, shares WFMZ, Dr. Chin Yee from Georgia Retina has performed the first…

    Continue Reading Georgia Retina Performs First Susvimo Implantation in State for Wet Macular Degeneration
    Minnesota to Begin Newborn Screening for Congenital Cytomegalovirus
    https://pixabay.com/en/baby-foot-blanket-newborn-child-1178539/

    Minnesota to Begin Newborn Screening for Congenital Cytomegalovirus

    Newborn screening is a public health program which screens infants for a variety of genetic, endocrine, and metabolic disorders following birth. For example, a newborn screening panel may test for…

    Continue Reading Minnesota to Begin Newborn Screening for Congenital Cytomegalovirus
    Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa
    jniittymaa0 / Pixabay

    Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa

    People with epidermolysis bullosa (EB) often experience symptoms such as intense itching or severe pain. Unfortunately, these symptoms can be debilitating and may greatly affect overall quality-of-life. However, some burgeoning…

    Continue Reading Study Shares Calcipotriol Benefits for Dystrophic Epidermolysis Bullosa